Literature DB >> 6548020

Production of VIP- and PHM (human PHI)-related peptides in human neuroblastoma cells.

M Hoshino, C Yanaihara, K Ogino, K Iguchi, H Sato, T Suzuki, N Yanaihara.   

Abstract

We demonstrated the production and release of a peptide structurally identical with porcine and bovine VIP-28 in human neuroblastoma NB-OK-1 cell line. In the cells, VIP-like immunoreactive (IR-VIP) components of 8 K dalton (Kd), 11 Kd, 18 Kd and 30 Kd were also detected and the 8 Kd and 18 Kd components were apparently released into the culture medium, indicating the possibility of less extended or limited processing of the VIP precursor in the cultured cells of tumor origin. The cells were also shown to produce, simultaneously with the VIP-28, a PHI/PHM-like immunoreactive (IR-PHI/PHM) component which coeluted with synthetic PHM-27, not PHI-27, in reverse-phase high performance liquid chromatography (HPLC). In addition to the PHM-27-like component, another IR-PHI/PHM component was detected in the cell extract which eluted in HPLC immediately before synthetic PHM-27 and crossreacted with PHI-27 amino-terminal specific antiserum but not with PHI-27 central-portion specific or PHM-27 carboxyl-terminal specific antiserum. The presence in NB-OK-1 cells of this IR-PHI/PHM component related to the amino-terminal portion of PHI/PHM suggested possible alternative(s) of post-translational processing of the VIP precursor in the cells in terms of the production of PHM-27-related peptides.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6548020     DOI: 10.1016/0196-9781(84)90199-2

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Peptide histidine isoleucine-like immunoreactivity release from the rat gastric fundus.

Authors:  D Currò; P Preziosi; E Ragazzoni; G Ciabattoni
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

2.  Expression of a urokinase-type plasminogen activator during tumor growth leads to angiogenesis via galanin activation in tumor-bearing mice.

Authors:  Hiroyuki Yamamoto; Rina Okada; Rika Tanaka; Keiko Unno; Kazuaki Iguchi
Journal:  FEBS Open Bio       Date:  2017-10-09       Impact factor: 2.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.